Treatment Outcomes of External Beam Radiation Therapy for Unresectable Locally Advanced Thyroid Cancer with or without Metastasis: A Retrospective Single-Center Study
| Autor: | Akira Anbai, Eriko Okuyama, Satoshi Kumagai, Manabu Hashimoto, Yuki Wada, Noriko Takagi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Larynx squamous cell thyroid cancer medicine.medical_specialty R895-920 Urology locally advanced thyroid cancer Single Center Metastasis external beam radiation therapy Medical physics. Medical radiology. Nuclear medicine 03 medical and health sciences 0302 clinical medicine tyrosine kinase inhibitor medicine.artery medicine Anaplastic carcinoma Common carotid artery Thyroid cancer Aorta business.industry General Medicine medicine.disease 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis business Progressive disease |
| Zdroj: | Radiation Volume 1 Issue 3 Pages 16-182 Radiation, Vol 1, Iss 16, Pp 174-182 (2021) |
| ISSN: | 2673-592X |
| DOI: | 10.3390/radiation1030016 |
| Popis: | We evaluated treatment outcomes of external beam radiation therapy (EBRT) for unresectable locally advanced thyroid cancer (LATC) with or without metastasis. We enrolled 11 LATC patients who underwent EBRT (median age: 76 (45–83) years six males and five females). Eastern Cooperative Oncology Group performance statuses of 0 (n = 3), 1 (n = 1), 2 (n = 6), and 3 (n = 1) were observed. Histologic types included papillary carcinoma (n = 5), anaplastic carcinoma (n = 3), and squamous cell carcinoma (n = 3). The organs invaded by the tumor that caused it to be deemed unresectable were common carotid artery (n = 5), trachea (n = 4), aorta (n = 1) and larynx (n = 1). The median follow-up time was 6 months. One, seven, two, and one patient showed complete response (CR), partial response (PR), stable disease, and progressive disease, respectively. The rate of local CR+PR was 73% moreover, 75% of patients achieved a > 30% tumor size reduction within 6 months. The median local progression-free survival of patients with local CR+PR was 11.5 (4–68) months. The median overall survival was 6 (1–68) months. Grade 3 acute complications occurred in five (45%) patients. No patients had Grade 4 or 5 complications. In conclusion, EBRT reduced the tumor volume in 75% of LATC patients without inducing severe toxicity. This therapy should be considered as a treatment option for LATC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|